5-Methoxy-diisopropyltryptamine
 |
This article needs additional citations for verification. (January 2012) (Learn how and when to remove this template message) |
 |
|
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | 4021-34-5  |
| PubChem (CID) | 151182 |
| DrugBank | DB01441  |
| ChemSpider | 133247 |
| ChEBI | CHEBI:48282 |
| Chemical and physical data | |
| Formula | C17H26N2O |
| Molar mass | 274.4 g/mol |
| 3D model (Jmol) | Interactive image |
| Melting point | 181 °C (358 °F) |
|
|
|
|
| (what is this?) (verify) |
|
5-methoxy-diisopropyltryptamine (5-MeO-DiPT), sometimes called "Foxy", is a psychedelic tryptamine. 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.
Contents
Effects[edit]
Erowid reports the following effects:[1]
Positive[edit]
- Mood lift, euphoria
- Intensification of tactile sensations, smell, etc.
- Sexually interesting
- Emotionally opening
- Diminished aggression, hostility, and jealousy
- Diminished fear, anxiety, and insecurity
- Improved self-confidence
- Substantial enhancement of the appreciation for quality of music
- Increased energy and endurance
Neutral[edit]
- Out-of-body experience, dissociation
- Feelings of body & muscle energy, buzzing
- Auditory distortions, pitch shifts
- Visual distortions, open and closed-eye patterning, movement trails, shifting colors
- Physical and mental stimulation
Negative[edit]
- Possible stomach discomfort, gas & vomiting
- Possible minor jaw-clenching
- Possible diarrhea
- Anxious stimulation
- Muscle tension / discomfort
- Possible male impotence for duration of drug's effects during higher doses
- Panic attacks
Pharmacology[edit]
The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as MAOI may be involved also.[2] The strongest receptor binding affinity for 5-MeO-DiPT is at the 5-HT1a receptor site.[3]
Overdosage[edit]
Excessive doses have caused clinical intoxication, characterized by nausea, vomiting, agitation, hypotension, mydriasis, tachycardia and hallucinations, in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose.[4] A 24-year-old man also died of this compound being administered into the colon.
Drug prohibition laws[edit]
China[edit]
As of October 2015 5-MeO-DiPT is a controlled substance in China.[5]
Denmark[edit]
Illegal since February 2004.
Germany[edit]
Illegal since September 1999.
Greece[edit]
Illegal since February 2003.
Japan[edit]
Illegal since April 2005.
Singapore[edit]
Illegal since early 2006.
Sweden[edit]
Sveriges riksdags health ministry Statens folkhälsoinstitut classified 5-MeO-DiPT as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Oct 1, 2004, in their regulation SFS 2004:696 listed as 5-metoxi-N,N-diisopropyltryptamin (5-MeO-DIPT), making it illegal to sell or possess.[6]
USA[edit]
On April 4, 2003, the United States DEA added both 5-MeO-DiPT and AMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004. Prior to its prohibition in the U.S., 5-MeO-DiPT was sold online alongside psychoactive analogues like DiPT, and DPT neither of which have yet been expressly outlawed in that country. However, in July 2004, Operation Web Tryp was concluded, confirming that U.S. Federal law enforcement intends to prosecute sale of these analogs of 5-MeO-DiPT. Previous prosecutions under the Federal Analog Act have met, on occasion, with failure, given some court rulings regarding possible unconstitutional vagueness regarding what substances are properly considered 'analogs'; such issues may be addressed on appeal.
See also[edit]
References[edit]
- ^ Erowid 5-MeO-DIPT Vault : Effects
- ^ Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2-3): 132–7. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
- ^ Ray TS (2 February 2010). "Psychedelics and the Human Receptorome". PLoS One. 5 (2). doi:10.1371/journal.pone.0009019. PMC 2814854
. PMID 20126400. - ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 975-976.
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- ^ http://www.notisum.se/rnp/sls/sfs/20040696.pdf
External links[edit]
- Official Ruling Placing 5-MeO-DIPT into Schedule I
- Erowid information on 5-MeO-DIPT.
- Erowid collection of rulings regarding constitutional and unconstitutional application of the analog act
- 5-MeO-DIPT entry in TiHKAL • info
